Praxis Precision Medicines, Inc. (PRAX) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Boston, MA, United States. Le PDG actuel est Marcio Silva De'Souza.
PRAX a date d'introduction en bourse 2020-10-16, 116 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $7.26B.
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders caused by neuronal imbalance. The company's lead candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor modulator in Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel inhibitor in Phase IIa development for essential tremor. Praxis is also advancing PRAX-562 for severe pediatric epilepsy and adult headache disorders, along with antisense oligonucleotide programs PRAX-222 and KCNT1 targeting genetic forms of epilepsy. Founded in 2015 and headquartered in Boston, Massachusetts, the company has established partnerships with RogCon Inc., Purdue Neuroscience Company, Ionis Pharmaceuticals, and The Florey Institute to support its clinical pipeline.
